Companies/Seres Therapeutics, Inc.

Company profile

Seres Therapeutics, Inc.

NASDAQ: MCRB · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0001609809Reports USD

#884 of 1,394 Healthcare companies by revenue

EA Score

53D

FH 55DQ 69GM 12SS 58

v0.1 · 65/100 weight · provisional

↑ net margin, return on equity · ↓ operating margin, growth stability

Methodology →

Revenue TTM

$1.1M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

$5.7M

Employees

103

Market cap

$75.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$789.0k$789.0k2025

Net income$5.7M$5.7M2025

Operating income-$94.0M-$94.0M2025

Total assets$138.2M$138.2M2025

Liabilities$94.0M$94.0M2025

Equity$44.2M$44.2M2025

Revenue trend

FY2018 – FY2025 · USD

$26.9M

FY18

$27.2M

FY19

$11.9M

FY20

$143.9M

FY21

$7.1M

FY22

$126.3M

FY23

FY25

$789.0k

FY25

Revenue by segment

Filed disclosures · FY2019

By product

License And Service100%

By geography

Not disclosed.

The read

Seres Therapeutics, Inc. booked $789.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a 721.9% net margin.

Peers · Healthcare

RetinalGenix Technologies Inc.——Vivani Medical, Inc.33D Cue Biopharma, Inc.50D Sera Prognostics, Inc.44D

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEORichard N. Kender

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: MCRB

Employees103

IPO date2015-06-26

Latest filings

8-K2026-07-08 8-K2026-07-08 8-K2026-06-05 8-K2026-06-01 10-Q2026-05-05 8-K2026-05-05 DEF 14A2026-04-27 8-K2026-03-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.